Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review

• Published in: Clinical rheumatology 2019-12, Vol.38 (12), p.3677-3687
• Main Authors: Obrișcă, Bogdan, Jurubiță, Roxana, Sorohan, Bogdan, Iliescu, Laura, Baston, Cătălin, Bobeică, Raluca, Andronesi, Andreea, Leca, Nicolae, Ismail, Gener
• Format: Article
• Language: English
• Subjects: Aged; Antiviral agents; Antiviral Agents - therapeutic use; Blood diseases; Case Based Review; Chronic infection; Cirrhosis; Cryoglobulinemia - complications; Cryoglobulinemia - virology; Cryoglobulins; Eradication; Female; Glomerulonephritis; Glomerulonephritis - drug therapy; Glomerulonephritis - virology; Hepatitis C; Hepatitis C - complications; Humans; Immunosuppressive agents; Infections; Liver cirrhosis; Male; Medicine; Medicine & Public Health; Middle Aged; Patients; Remission; Retrospective Studies; Rheumatology; Ritonavir; Treatment Outcome; Vasculitis
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-019-04625-y

Newer treatment protocols involving direct-acting antiviral agents (DAAs) have been associated with high rates of sustained virologic response (SVR) and clinical remission in patients with hepatitis C virus (HCV) associated cryoglobulinemic vasculitis (HCV-CV), but clinical response in those with renal involvement is less clear. Our goal was to evaluate the clinical course following DAA therapy in one of the largest cohorts of patients with HCV-associated cryoglobulinemic glomerulonephritis (HCV-GN) reported to date. This is an observational study of patients with chronic HCV infection and circulating cryoglobulins (CC) treated with DAAs in our department from January 2015 to January 2019. We identified a total of 67 patients with HCV and CC out of which nine patients fulfilled the criteria of HCV-GN and had adequate clinical follow-up time. We describe a cohort of nine patients with a mean age of 57 years and known duration of HCV infection ranging 3–20 years (four with evidence of compensated cirrhosis). All patients received the ritonavir-boosted paritaprevir/ombitasvir/dasabuvir regimen for 12 weeks and achieved SVR without subsequent viral relapse. Following DAAs completion, one patient developed “new-onset” cryoglobulinemic glomerulonephritis, six showed either persistent or worsening glomerulonephritis, and only two patients had a complete clinical response (CCR). Of the six patients with either persistent or worsening CV, 67% received additional immunosuppressive (IS) therapy for uncontrolled CV. Of the two patients that had a CCR, one patient received prior IS therapy while the other one improved without any additional intervention. Newer HCV treatment protocols involving DAAs are highly successful in eradication of HCV infection; however, in our experience, DAA treatment alone is insufficient in improving the renal outcomes of patients with HCV-GN and additional IS therapies should be considered.